United Therapeutics Accounts Payable

United Therapeutics's accounts payable stands at $500M as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

United Therapeutics reported $500M in accounts payable versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how United Therapeutics's accounts payable evolved across reporting periods, while the comparison chart places UTHR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. United Therapeutics's reading of $500M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.